PEGINTERFERON ALFA-2A [40KD] PLUS ADEFOVIR FOR 96 WEEKS IN HBEAG-NEGATIVE CHB RESULTS IN HIGH RATES OF HBSAG CLEARANCE/SEROCONVERSION

被引：1
|
作者：
Cao, Z. [1 ]
Yu, H. [1 ]
Ma, L. [1 ]
Zhang, Y. [1 ]
Liu, Y. [1 ]
Ma, B. [1 ]
Wu, H. [1 ]
Chen, X. [1 ]
机构：
[1] Beijing Youan Hosp, Beijing, Peoples R China
来源：
JOURNAL OF HEPATOLOGY | 2011年 / 54卷
关键词：
D O I：
10.1016/S0168-8278(11)60707-1
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
705
引用
收藏
页码：S283 / S283
页数：1
相关论文
共 50 条
  • [21] RESPONSE TO PEGINTERFERON ALFA-2A IN HBEAG-NEGATIVE CHB: BASELINE AND ON-TREATMENT KINETICS OF HBSAG SERUM LEVELS VARY ACCORDING TO HBV GENOTYPE
    Brunetto, Maurizia R.
    Marcellin, Patrick
    Cherubini, Beatrice
    Yurdaydin, Cihan
    Farci, Patrizia
    Hadziyannis, Stephanos J.
    Rothe, Vivien
    Regep, Loredana
    Kapprell, Hans-Peter
    Bonino, Ferruccio
    HEPATOLOGY, 2011, 54 : 1059A - 1059A
  • [22] Factors associated with sustained virologic response 1 year after treatment with peginterferon alfa-2A (40KD) (PEGASYS®) monotherapy for HBEAG-negative chronic hepatitis B
    Marcellin, P
    Bonino, F
    Lau, GY
    Farci, P
    Yurdaydin, C
    Piratvisuth, T
    Jin, R
    Gurel, S
    Hadziyannis, S
    Lu, ZM
    Popescu, M
    HEPATOLOGY, 2005, 42 (04) : 580A - 580A
  • [23] Serum HBV RNA is an Early Predictor of HBeAg Seroconversion in Patients with Chronic Hepatitis B (CHB) Treated with Pegylated Interferon Alfa-2a (40KD)
    van Boemmel, Florian
    van Boemmel, Alena
    Krauel, Alexander
    He, Hua
    Wat, Cynthia
    Pavlovic, Vedran
    Yang, Lei
    Deichsel, Danilo
    Berg, Thomas
    Boehm, Stephan
    HEPATOLOGY, 2015, 62 : 336A - 336A
  • [24] Efficacy and Safety of Peginterferon alfa-2a (40KD) in HBeAg-positive Chronic Hepatitis B Patients
    Caruntu, Florin Alexandru
    Streinu-Cercel, Adrian
    Gheorghe, Liliana Simona
    Grigorescu, Mircea
    Sporea, Ioan
    Stanciu, Carol
    Andronescu, Dan
    Voinea, Florea
    Diculescu, Mircea
    Oproiu, Alexandru
    Voiosu, Rodu
    JOURNAL OF GASTROINTESTINAL AND LIVER DISEASES, 2009, 18 (04) : 425 - 431
  • [25] On-treatment HBsAg decline in HBeAg-negative patients as a predictor of response to peginterferon alfa-2a (40kd) therapy 3 years post-treatment: Potential for response-guided therapy
    Brunetto, M.
    Bonino, E.
    Lau, G. K. K.
    Farci, R.
    Yurdaydin, C.
    Piratvisuth, T.
    Hadziyannis, S.
    Lu, Z. -M.
    Wu, J.
    Popescu, M.
    Marcellin, P.
    JOURNAL OF HEPATOLOGY, 2008, 48 : S254 - S254
  • [26] INTRAHEPATIC HBSAG PREDICTS TREATMENT RESPONSE IN HBEAG NEGATIVE CHRONIC HEPATITIS B (CHB) PATIENTS TREATED WITH PEGINTERFERON ALFA-2A AND ADEFOVIR; AN INTERIM ANALYSIS
    Takkenberg, B.
    De Niet, A.
    Terpstra, V.
    Zaaijer, H.
    Weegink, C.
    Koot, M.
    Dijkgraaf, M.
    Jansen, P.
    Beld, M.
    Reesink, H.
    JOURNAL OF HEPATOLOGY, 2010, 52 : S397 - S397
  • [27] Characterization of Hepatitis B Surface Proteins in HBeAg-positive Patients with Chronic Hepatitis B (CHB) Treated With PegInterferon Alfa-2a (40KD)
    Rinker, Franziska
    Bremer, Corinna M.
    Wiegand, Steffen B.
    Bremer, Birgit
    Manns, Michael P.
    Wedemeyer, Heiner
    Yang, Lei
    Pavlovic, Vedran
    Wat, Cynthia
    Glebe, Dieter
    Kraft, Anke R.
    Cornberg, Markus
    HEPATOLOGY, 2015, 62 : 1196A - 1197A
  • [28] ON-TREATMENT HBSAG DECLINE DURING PEGINTERFERON ALFA-2A (40KD) ± LAMIVUDINE IN PATIENTS WITH HBEAG-POSITIVE CHB AS A POTENTIAL PREDICTOR OF DURABLE OFF-TREATMENT RESPONSE
    Lau, George K.
    Marcellin, Patrick
    Brunetto, Maurizia
    Piratvisuth, Teerha
    Kapprell, Hans-Peter
    Button, Peter
    Batrla, Richard
    HEPATOLOGY, 2008, 48 (04) : 714A - 714A
  • [29] Sustained response to peginterferon alfa-2a (40 kD) with or without lamivudine in Asian patients with HBeAg-positive and HBeAg-negative chronic hepatitis B
    Piratvisuth, Teerha
    Lau, George
    Chao, You-Chen
    Jin, Rui
    Chutaputti, Anuchit
    Zhang, Q. -B.
    Tanwandee, Tawesak
    Button, Peter
    Popescu, Matei
    HEPATOLOGY INTERNATIONAL, 2008, 2 (01) : 102 - 110
  • [30] Profound on-treatment viral suppression with peginterferon alfa-2a (40KD) (PEGASYS®) plus lamivudine combination therapy limits the development of YMDD mutations, but does not improve sustained response rates over peginterferon alfa-2a (40KD) alone
    Germanidis, G
    Marcellin, P
    Lau, G
    Bonino, F
    Farci, P
    Hadziyannis, S
    Jin, R
    Yao, GB
    Piratvisuth, T
    Yurdaydin, C
    Diago, M
    Gurel, S
    Lai, MY
    Popescu, M
    Pluck, N
    HEPATOLOGY, 2004, 40 (04) : 653A - 653A
12345